Is this email not displaying correctly?
View it in your browser.
Newswise - News for Journalists

Newswise Special Wire
Tuesday, January 12, 2016

Public edition |

Newswise Cancer Research Wire for 12-Jan-2016

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

Scientists Identify Molecule That Appears to Fuel Deadly Genetic Illness

Researchers identified a molecular target and experimental treatment strategy for DNA repair defects behind Fanconi anemia – a complex genetic disorder responsible for birth anomalies, organ damage, anemia and cancer.

 • Image(s) embedded •  (Embargo expired on 12-Jan-2016 at 12:00 ET)

Stem Cell Reports - Jan. 12, 2016; National Institutes of Health-R01CA102357

– Cincinnati Children's Hospital Medical Center

Cancer-Killing Proteins Destroy Tumor Cells in Bloodstream

Cornell researchers have discovered potent cancer-killing proteins that can travel by white blood cells to kill tumors in the bloodstream of mice with metastatic prostate cancer.

Journal of Controlled Release

– Cornell University

Researchers Develop Simple Paper Test That Quickly Diagnoses Illnesses by Changing Colour

A multi-disciplinary team of researchers has developed a new diagnostic test that makes it possible for patients to quickly determine if they are infected with an illness, using a simple paper test sensitive enough to detect markers of various illnesses using minute amounts of blood, sweat, or other biological material.

 • Image(s) embedded • 

Angewandte Chemie

– McMaster University

Making a Safe Procedure Even Safer

In a comprehensive modeling study, researchers from UC Davis and other institutions have found that breast cancer screening with digital mammography poses only a small risk of radiation-induced breast cancer for most women. However, the research showed increased risk for women with large breasts or breast implants, who must often receive extra screening views, increasing their radiation exposure.

(Embargo expired on 11-Jan-2016 at 17:00 ET)

Annals of Internal Medicine

– UC Davis Comprehensive Cancer Center

McMaster Researchers Reveal Predictive Staircase to Leukemia

Researchers detail how they have been able to fingerprint myelodysplastic syndromes (MDS), a state for blood cells that turns into acute myeloid leukemia (AML) cancer in approximately 30% of patients

(Embargo expired on 11-Jan-2016 at 12:00 ET)

Cancer Cell

– McMaster University

More Research Needed on Evaluation of Dense Breasts

A systematic review of the scientific literature on dense breasts by researchers at UC Davis and other institutions has found that determinations of breast density can be unreliable and that as many as 19 percent of women are re-categorized as dense rather than non-dense or vice versa from one mammogram to the next. The study also found that supplemental diagnostic screenings for women with dense breasts find additional breast cancers but also greatly increase false positive results.

(Embargo expired on 11-Jan-2016 at 17:00 ET)

Annals of Internal Medicine, Jan-2016

– UC Davis Comprehensive Cancer Center

USPSTF Breast Cancer Screening Recommendations Could Endanger Women

If followed, new U.S. Preventive Services Task Force (USPSTF) breast cancer screening recommendations will result in thousands of unnecessary deaths each year and thousands more women enduring extensive and expensive treatment than if their cancer had been found early by an annual mammogram.

 • Image(s) embedded •  (Embargo expired on 11-Jan-2016 at 17:00 ET)

– American College of Radiology (ACR)

New Analyses Confirms Biennial Mammography Starting at Age 50 Is Optimal for Average Women

New and comprehensive analyses from six independent research teams examining breast cancer screening intervals have produced a unanimous finding — that mammography screening every two years for average risk women ages 50 to 74 offers a favorable balance of benefits to harm.

(Embargo expired on 11-Jan-2016 at 17:00 ET)

Annals of Internal Medicine; U01 CA152958, RO1CA154292, HSN261201100031C, U54CA163303

– Georgetown Lombardi Comprehensive Cancer Center

Study Reveals Potential Therapy Targets for Triple-Negative Breast Cancer

In cancer, cell signaling pathways are the critical chain of events that can either quash or quicken disease progression.

(Embargo expired on 11-Jan-2016 at 11:00 ET)

Nature Cell Biology

– University of Texas M. D. Anderson Cancer Center

Blood Test That Monitors Dead Cancer Cell DNA Better at Tracking Spread of Melanoma

A new study shows that a blood test which monitors blood levels of DNA fragments from dead cancer cells does a better job than the current standard test at tracking the severity and potential spread of metastatic melanoma. The study, by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, is set for publication tomorrow in the January edition of Molecular Oncology.

Molecular Oncology

– NYU Langone Medical Center

Disparity Lies at Intersection of HIV, Hodgkin Lymphoma

Among HIV-positive patients with Hodgkin lymphoma, a new study finds that blacks are significantly less likely than whites to receive treatment for the cancer, even though chemotherapy saves lives.

 • Image(s) embedded • 


– Brown University

University of Kentucky Chemistry Researchers Develop Metal Complexes to Study Cancer

UK chemistry researchers and graduate students recently published a study showing that specialized compounds containing the metal ruthenium may be able to recognize or damage specific DNA structures relevant for cancer.

 • Image(s) embedded • 

Chemistry - A European Journal

– University of Kentucky

A Novel Gene Alteration Associates with Aggressive Prostate Cancer in African American Men

It is well established that prostate cancer is more prevalent in African American men when compared to men of other ethnicities. There has been a premise that a combination of genetics, lifestyle, nutritional and medical access reasons led to the significant statistical difference. However, in their study titled, “A Novel Genomic Alteration of LSAMP associates with Aggressive Prostate Cancer in African American Men,” published in EBioMedicine ( S2352396415301870), researchers from Uniformed Services University of the Health Sciences (USU), Walter Reed National Military Medical Center, DoD’s Joint Pathology Center (JPC), Dana-Farber Cancer Research Institute (DFCI), Genomatix GmbH and CytoTest, Inc., found some distinct genomic variations that also could be to blame.


– Uniformed Services University of the Health Sciences (USU)

Unusual Drug Target and Drug Generate Exciting Preclinical Results in Mouse Models of Metastatic Breast Cancer

A doctor treating a patient with a potentially fatal metastatic breast tumor would be very pleased to find, after administering a round of treatment, that the primary tumor had undergone a change in character – from aggressive to static, and no longer shedding cells that can colonize distant organs of the body. Indeed, most patients with breast and other forms of cancer who succumb to the illness do so because of the cancer’s unstoppable spread.

 • Image(s) embedded • 

Genes & Development

– Cold Spring Harbor Laboratory

New Pathway to Differentiation Found, Shedding Light on Some Cancers

UAB researchers have discovered a new mechanism of differentiation, as studied in megakaryocytes, the blood cells responsible for platelet production. The ultimate effect of this new pathway is an alternative splicing of messenger RNAs.

– University of Alabama at Birmingham

NUS Researchers Discover New Potential Treatment for Colorectal Cancer

A study led by researchers from the Cancer Science Institute of Singapore at the National University of Singapore has demonstrated the efficiency of a small molecule drug, PRIMA-1met, in inhibiting the growth of colorectal cancer cells. Colorectal cancer is the cancer of the large intestine (colon and rectum) and is the most common cancer in Singapore.

 • Image(s) embedded • 


– National University of Singapore

Study Finds Gaps in Patient Knowledge of Breast Reconstruction Surgery and Complications

In a study published in the journal Annals of Surgery, researchers report that breast cancer patients surveyed about their knowledge of breast reconstruction were only moderately informed about the procedure, and their knowledge of complications was low.

Annals of Surgery, Dec-2015

– University of North Carolina Health Care System

New Drug May Overcome Treatment Resistance in a High-Risk Children's Cancer

A new-generation drug has unprecedented potency against neuroblastoma tumors that develop resistance to the anticancer drug crizotinib. A preclinical study supports fast-tracking the agent into pediatric clinical trials this year.

 • Image(s) embedded • 

Cancer Discovery, published online Nov 10, 2015 and in print Jan. 8, 2016; CA140198

– Children's Hospital of Philadelphia

Landmark Study Shows Superiority of Chromoendoscopy in Dysplasia Detection in Patients with Colitis

Mount Sinai Researchers Led Long-Term Surveillance Study, First of its Kind, Showing Chromoendoscopy More Effective than Standard Colonoscopy in These Patients

Clinical Gastroenterology and Hepatology

– Mount Sinai Health System

UNC Lineberger Researchers Uncover Promising Direction for the Treatment of Pancreatic Cancers Driven by KRAS Mutation

In the journal Cancer Cell, UNC Lineberger researchers report findings of a promising strategy to treat KRAS-mutant pancreatic cancers. Preclinical studies showed promise for using a type of investigational drug that works by inhibiting the protein ERK, the last of a series of signals of a signaling pathway that drives drive abnormal growth of cells with KRAS mutations.

 • Image(s) embedded • 

Cancer Cell, Dec-2015

– University of North Carolina Health Care System

Blocking Melanoma’s Escape: How Personalized Trials in Avatars Break Therapy Resistance in Relapsed Cancers

By utilizing a revolutionary method that allows mice to serve as “avatars” for patients, scientists at The Wistar Institute have shown that a previously ineffective targeted drug for melanoma may actually be quite potent in halting the progression of disease in certain patients.

 • Image(s) embedded • 

Clinical Cancer Research, Dec-2015; PO1 CA114046; P01 CA025874; P30 CA010815; R01 CA047159; RO1 24 CA174746-01; CA010815 ; P30CA016672

– Wistar Institute

Early Trial Shows Injectable Agent Illuminates Cancer During Surgery

Doctors at the Duke University School of Medicine have tested a new injectable agent that causes cancer cells in a tumor to fluoresce, potentially increasing a surgeon’s ability to locate and remove all of a cancerous tumor on the first attempt. The imaging technology was developed through collaboration with scientists at Duke, the Massachusetts Institute of Technology (MIT) and Lumicell Inc.

 • Image(s) embedded •  (Embargo expired on 06-Jan-2016 at 14:00 ET)

Science Translational Medicine; T32GM007171, 1U43CA165024, UL1TR001117, 5P30-CA-014236-38

– Duke Medicine

Rehabilitation Oncology Now Published by Wolters Kluwer

The leading resource for cancer physical therapy and rehabilitation professionals, Rehabilitation Oncology, official journal of the Oncology Section of the American Physical Therapy Association (APTA), commences a publishing partnership with Wolters Kluwer with the January 2016 issue.

Rehabilitation Oncology

– Wolters Kluwer Health: Lippincott Williams and Wilkins

UC San Diego Researchers Link Higher Risk of Leukemia to Low Sunlight and Vitamin D

Epidemiologists at University of California, San Diego School of Medicine report that persons residing at higher latitudes, with lower sunlight/ultraviolet B (UVB) exposure and greater prevalence of vitamin D deficiency, are at least two times at greater risk of developing leukemia than equatorial populations.

 • Image(s) embedded • 


– University of California, San Diego Health Sciences

UCLA Scientists Test New Strategy That Could Help Fight Ovarian Cancer

UCLA scientists have developed a promising novel method to treat gynecologic tumors. The approach focuses on a protein called p53, which is commonly mutated in women who have high-grade serous ovarian cancer, the deadliest form of reproductive cancer. In many women with the disease, the cancer is very advanced by the time it is diagnosed and is therefore difficult to treat.

 • Image(s) embedded • 

– University of California, Los Angeles (UCLA), Health Sciences

New FAU Study Suggests Benefits of Regular Mammography Extend to the Elderly

Although a number of randomized trials demonstrate the clear benefits of mammography screening in women up to age 74 on reducing mortality, data are sparse in women over the age of 74, especially minorities. A new study shows that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.

 • Image(s) embedded • 

The American Journal of Medicine

– Florida Atlantic University

Study: Most Men Not Getting Prostate Cancer Screening, Treatment Information They Need

Researchers at the University of Nebraska Medical Center and the University of Memphis recently published an article in the American Journal of Men’s Health which found that men and their health providers are not having important discussions when it comes to prostate cancer screening and treatment.

 • Audio / Image(s) embedded • 

American Journal of Men's Health

– University of Nebraska Medical Center (UNMC)

Palliative Care Offers Greater Cost Savings for Cancer Patients with Multiple Chronic Conditions

Patients with incurable cancer and numerous other serious health conditions who consulted with a palliative care team within two days of hospitalization had significant savings in hospital costs, according to a new study led by researchers at the Icahn School of Medicine at Mount Sinai.

(Embargo expired on 05-Jan-2016 at 17:00 ET)

Health Affairs

– Mount Sinai Health System

Cancer Cells Poised for Growth When Opportunity Knocks

Researchers have identified a mechanism that allows cancer cells to respond and grow rapidly when levels of sugar in the blood rise. This may help to explain why people who develop conditions in which they have chronically high sugar levels in their blood, such as obesity, also have an increased risk of developing certain types of cancer.

 • Image(s) embedded • 

eLife, Nov-2015

– MRC Clinical Sciences Centre/Institute of Clinical Sciences (ICS) Faculty of Medicine, Imperial College London

UNC Lineberger Researchers Identify DNA Repair Enzyme as a Potential Brain Cancer Drug Target

In the journal Cell Reports, UNC Lineberger researchers report that when they removed Dicer from preclinical models of medulloblastoma, a common type of brain cancer in children, they found high levels of DNA damage in the cancer cells, leading to the cells’ death. The tumor cells were smaller, and also more sensitive to chemotherapy.

 • Image(s) embedded • 

Cell Reports, Dec-2015

– University of North Carolina Health Care System

Novel RNA Delivery System May Treat Incurable Blood Cancers

Tel Aviv University researchers develop unique system to deliver therapy at site of Mantle Cell Lymphoma.

Proceedings of the National Academy of Sciences

– American Friends of Tel Aviv University

New Paste Prevents Scarring Caused by Radiation Therapy for Cancer

An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy. That is according to a study led by researchers at Laura and Isaac Perlmutter Cancer Center to be published tomorrow in the January edition of the Journal of the Federation of American Societies for Experimental Biology, or FASEB.


– NYU Langone Medical Center

Prostate Cancer Surveillance Criteria May Not Be Accurate for African American Men

When to stop watchful waiting and begin definitive treatment of African American patients explored in The Journal of Urology.

Journal of Urology

– Elsevier, Inc.

Weizmann Institute Drug, TOOKAD® Soluble, Approved in Mexico for Prostate Cancer Therapy

The Weizmann Institute-developed TOOKAD® Soluble has been approved in Mexico for use in treating prostate cancer. The therapy, which has no side effects, offers men with early-stage prostate cancer a much-needed treatment alternative. Phase III trials have taken place in Europe and continue in the U.S.

 • Image(s) embedded • 

– Weizmann Institute of Science

Gene Thought to Suppress Cancer May Actually Promote Spread of Colorectal Cancer

A gene that is known to suppress the growth and spread of many types of cancer has the opposite effect in some forms of colorectal cancer, University of Missouri School of Medicine researchers have found. It is a finding that may lay the foundation for new colorectal cancer treatments.

 • Image(s) embedded • 

Oncogene; CA150081 ; DC010387

– University of Missouri Health

January JACR: Public Education Eases Anxiety About Screening Mammography

The January Journal of the American College of Radiology (JACR) offers articles highlighting radiologists’ involvement in educating patients about mammography and making imaging safer for children.

 • Image(s) embedded • 

Journal of the American College of Radiology

– American College of Radiology (ACR)

Mayo Study: Radiation an Important Addition to Treatment for Pancreatic Cancer Surgery Candidates

Radiation therapy was associated with a lower risk of cancer recurrence in pancreatic cancer surgery patients, making it, like chemotherapy, an important addition to treatment, Mayo Clinic research found.

International Journal of Radiation Oncology, Biology, Physics

– Mayo Clinic


NASA Awards Funds to UT Southwestern Researchers to Study Effects of Space Radiation During a Mars Mission

UT Southwestern Medical Center researchers have been awarded $3.6 million in NASA funds to study how space radiation would affect the cancer risk of astronauts taking part in deep space missions to Mars.

 • Image(s) embedded • 

– UT Southwestern Medical Center

MD Anderson and Enumeral Enter Into Collaborative Research and Development Agreement

The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement with Enumeral Biomedical Holdings Inc.

– University of Texas M. D. Anderson Cancer Center

UF Health Cancer Center - Orlando Health Opens at South Lake Hospital

South Lake Hospital, in affiliation with Orlando Health, has added a new collaborative cancer center to its growing medical campus. Set to open January 11, 2016, the new center, which will provide radiation oncology services, will be managed by UF Health Cancer Center - Orlando Health and Integrated Oncology Network (ION) and give patients in and around Lake County local access to the cancer center specialists, vast resources, leading-edge treatments and ongoing medical trials.

 • Image(s) embedded • 

– Orlando Health

Sally Vernon, Ph.D., Appointed to National Cancer Institute Board

Sally Vernon, Ph.D., chair of the Department of Health Promotion and Behavioral Sciences at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, has been appointed to the Board of Scientific Counselors for Clinical Sciences and Epidemiology at the National Cancer Institute (NCI).

 • Image(s) embedded • 

– University of Texas Health Science Center at Houston

MD Anderson and Kymab Announce Research and Development Strategic Partnership in Immuno-Oncology

Kymab, a leading human monoclonal antibody biopharmaceutical company, and The University of Texas MD Anderson Oncology Research for Biologics and Immunotherapy Translation (ORBIT) unit today announced a strategic cancer drug discovery and development alliance.

(Embargo expired on 07-Jan-2016 at 04:00 ET)

– University of Texas M. D. Anderson Cancer Center

NCCN Awarded $2 Million in Research Funding From Peregrine Pharmaceuticals to Study Bavituximab in Various Cancers

The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Peregrine Pharmaceuticals, Inc. to facilitate studies of bavituximab in various cancers.

– National Comprehensive Cancer Network® (NCCN®)

Training the Next Generation of Cancer Surgeons at Rutgers

Aiming to enhance the training of cancer surgeons, a two-year fellowship program is now being offered by Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School. The program offers board-eligible surgeons an opportunity to subspecialize in the intricacies of cancer care both in the clinical and research arenas.

 • Image(s) embedded • 

– Rutgers Cancer Institute of New Jersey

SGO’s Foundation for Gynecologic Oncology Merges with Foundation for Women’s Cancer

Gynecologic oncology research, education and awareness took a historic step forward on Jan. 1, 2016, when the Society of Gynecologic Oncology’s Foundation for Gynecology Oncology and the Foundation for Women’s Cancer (FWC) became one foundation within the SGO.

– Society of Gynecologic Oncology

NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic Malignancies

The NCCN Oncology Research Program has awarded three research grants to investigate the safety and effectiveness of volasertib in hematologic malignancies.

– National Comprehensive Cancer Network® (NCCN®)

Expert Pitch

Cervical Health: Pathologist Expert Explains HPV, Pap Testing, Cervical Cancer

 • Image(s) embedded • 

– College of American Pathologists (CAP)

#Breastcancer experts can discuss screening guidelines based on research @ucdavis. #radiation exposure and dense #breasts

 • Image(s) embedded •  (Embargo expired on 11-Jan-2016 at 17:00 ET)

– UC Davis Comprehensive Cancer Center

Cedars-Sinai Breast Cancer Expert Discusses Latest Mammogram Guidelines and Controversy in New Video

 • Video embedded •  (Embargo expired on 11-Jan-2016 at 17:00 ET)

– Cedars-Sinai

Moon Chen, #Cancerdisparities Expert @UCD_Cancer, Can Discuss New #Cancer Data From @Americancancer Incl. Higher Mortality in Apis, Latinos

 • Image(s) embedded • 

– UC Davis Comprehensive Cancer Center

subscribe/unsubscribe :: edit my preferences
© 2016 Newswise, Inc. All Rights Reserved. | 215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417 | Contact Us